Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Key Stats

• Today's Range: $0.59 to $0.65
• 50-Day Range: $0.51 to $0.67
• 52-Week Range: $0.47 to $9.60
• Volume: 42,998 shs
• Average Volume: 182,913 shs
• Market Capitalization: $3.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

MTNB Stock Analysis - Frequently Asked Questions

How have MTNB shares performed this year?

Matinas Biopharma's stock was trading at $0.51 on January 1st, 2025. Since then, MTNB stock has increased by 19.6% and is now trading at $0.61.
View the best growth stocks for 2025 here.

How were Matinas Biopharma's earnings last quarter?

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).

How do I buy shares of Matinas Biopharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Matinas Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 5/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:MTNB
• Previous Symbol: NYSE:MTNB
• CIK: 1582554
• Web: N/A
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -123.06%
• Return on Assets: -94.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 5.53

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 2.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.43 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 5,087,000
• Free Float: 4,599,000
• Market Cap: $3.10 million
• Optionable: N/A
• Beta: 1.19